Oxford Bio’s recently-appointed chief executive, Dr Frank Mathias, said buying ABL would contribute to the company’s strategy to transition to a pure-play CDMO focusing on the cell and gene ...

This drug targets the protein tyrosine kinase encoded by the BCR-ABL gene, which is located on the Ph. Up to 85% of patients treated with 400 mg imatinib achieve a complete cytogenetic response ...

Imatinib is widely used in the treatment of chronic myeloid leukemia (CML), a disorder characterized by the presence of the BCR-ABL fusion gene; however, the therapeutic options for patients with ...